Dry Powder Inhaler Market
Market Insights on Dry Powder Inhaler covering sales outlook, demand forecast & up-to-date key trends
Dry Powder Inhaler Market by Product - (Single Dose Dry Powder Inhalers and Multi Dose Dry Powder Inhalers), by Indication- (Asthma, Chronic Obstructive Pulmonary Disease (COPD) & Region for 2021-2031
Dry Powder Inhaler Market Snapshot
[371 Pages Report] Global Dry Powder Inhaler Market is set to experience a significant growth of 4.6% CAGR from 2021 to 2031, with an estimated market value of around US$ 18.9 Bn as of 2021. As per Future Market Insights’ projections, Manually Operated Inhaler Devices hold a substantial share of over 70.9% in 2021 within the global dry powder inhaler market.
Market Outlook:
|
Data Points |
Market Insights |
|
Market Value 2020 |
US$ 18.1 Bn |
|
Market Value 2021 |
US$ 18.9 Bn |
|
Market Value 2031 |
US$ 29.6 Bn |
|
CAGR 2021-2031 |
4.6% |
|
Market Share of Top 5 Countries |
60.5% |
|
Key Market Players |
GlaxoSmithKline Plc, AstraZeneca Plc, Novartis AG, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A., Elpen S.A., Vectura Group Plc, Beximco Pharmaceuticals Ltd., Hovione, AptarGroup, Inc., Iconovo AB (Stevanato Group), Sava Healthcare Ltd., MannKind Corporation, Mylan N.V(a part of Viatris) and Pharmaxis |
With the utilization of dry powder inhalers in the treatment of a diverse range of diseases, the development of technologically innovative products is surfacing. These “smart technologies” are set to satisfy specific market requirements for the development of cost-effective drug products.
The deep penetration of digital systems into the inhaler market has been advantageous in terms of ruling out several device and design errors. The implementation of microprocessors in inhalers for supporting patients with device usage and handling is positively impacting compliance and product satisfaction.
The development of next-generation inhalers with the integration of smart technologies is likely to drive the growth of the dry powder inhaler market. The integration is set to establish a breakthrough in drug delivery with the primary basis being a tailored performance based on the patient’s/user’s variable breathing patterns.
Technologically advanced dry powder inhalers with digitally enabled platforms along with a friendly user interface will help in preventing or compensating actuation errors that, in turn, will enhance compliance. The growth of digitally operated inhalers devices is also supported by the recent upsurge in digitalization in the healthcare and industrial sectors. This factor will drive the dry powder inhaler market.
The dry powder inhalers are a preferred method of treatment of respiratory ailments over pressurized metered dose inhalers and nebulizers owing to the rising concerns related to the environmental impact of inhaler devices which utilize chloroflouro carbons as propellants.
Thus, the production and design of dry powder inhalers is set to witness a growth over the forecast period, and is expected to offer product manufacturers or key players in the dry powder inhaler market with an optimistic growth opportunity.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
4.56% |
|
H1, 2022 Projected |
4.57% |
|
H1, 2022 Outlook |
4.17% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 40 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 39 ↓ |
The global dry powder inhaler market is subject to regulatory changes and device compliance guidelines as per the macroeconomic and industry standards. Comparative analysis of H1-2022 and H1-2021 revealed insights on the market dynamics role on the global market growth.
H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 40 BPS. However, In H1-2022, the market growth rate of dry powder inhalers is expected to fall by 39 basis point share (BPS), as per FMI analysis.
The value change in BPS presents a decline owed to the low adoption rate of dry powder inhalers because of their higher unit cost when compared with standard metered dose inhalers. Moreover, some modalities of dry powder inhalers present issues with drug device interaction, as well as differential patient outcomes owed to the variability in breath actuation as per individual capability.
However, owed to the sustainable development of medical devices, dry powder inhalers propose a reduced emission of aerosols which are harmful to the environment. With a reduced carbon footprint, the market is set to witness an increased uptake over the forecasted years.
Sales Analysis Of Dry Powder Inhalers From 2016 To 2020 Vs Market Outlook For 2021 To 2031
The dry powder inhaler market holds nearly 47.4% of the overall US$ 38.2 Bn respiratory inhalers market in 2020.
The rising global incidence of respiratory disorders such as chronic obstructive pulmonary disease, asthma and even cystic fibrosis has established a worldwide need of dry powder inhalers. Moreover, the increasing air pollution levels, particularly in developing and emerging regions, combined with a surge in the healthcare per capita spending have further bolstered the demand and consumption of dry powder inhaler market over the globe.
Dry powder inhaler devices are commonly utilized to deliver medications into the lungs, such as inhaled corticosteroids. These inhaler devices are breath actuated and the drug is released into the airway only after a deep and fast breath inhalation into the lungs.
Conventional inhalers deliver a puff of medicine whereas, the dry powdered formulation delivered by dry powder inhaler devices delivers a select dose of drug into the lungs, following which the DE agglomeration of drug takes place for quicker effect into the patient’s lungs.
One of the major advantages of dry powder inhalers is that they are also applicable for use in a varied range of diseases. These devices take into account the patient-device interaction, which is a complex process and is highly dependent upon the patient aspiration rate as well as the force of inhalation.
Moreover, there has been observed, an increasing focus of development in high dose drug delivery, systemic delivery as well as vaccinations via the pulmonary pathway. Hence, the development of specifically designed dry powder inhalers, tailored for patient’s indication as well as the type and units of doses they may require is expected to be a preferred form of drug delivery over the forecast period with cost effective and safe applications.
The market is expected to expand at a considerable growth rate over the next ten years at a CAGR of close to 4.6%, and offer an absolute $ opportunity of US$ 861.0 Mn from 2021 to 2022.
What Are The Key Opportunities For Dry Powder Inhalers Manufacturers?
Confounding problems are existent in clinical trials for dry powder inhalers, specifically, where the possibility of errors by patients with respect to inhaler handling can be high. Distinguishing handling errors by patients from existing clinical effects is complex, particularly in phase III trials where support to patients cannot be contracted.
The impact of digital systems thus presents an opportunity to assist with monitoring and control over all phases of clinical studies. Digital technology can improve clinical outcomes by improving adherence and reducing patient errors through mobile applications connected to the device, which will deliver useful tools including reminders and step-based guidance for the appropriate technique of usage.
On the other hand, medical providers can track patient compliance to the therapeutic regimen in real time. Additionally, the monitoring of symptoms and their worsening is registered along with the compliance tracker and it assists with the prevention of severe disease exacerbations, thus leading to a satisfying patient outcome.
The development of inhalation products poses the possibility of significant errors for drug-device combinations related to the usage of the device by patients, variations in the delivery of drugs, as well as flawed data collection.
These errors may deliver distorted information regarding the therapeutic efficacy of drug formulations and device-based effects in clinical trials. The introduction of programmed tools for use in clinical trials will contribute to an improved understanding of drug-device combinations and their efficiency.
These tools may assist with enhanced data collection processes without being influenced by poor patient compliance as well as administration issues. These automated tools can include incorporated audio-based technologies and devices for monitoring medication compliance.
Connected wearable devices can be beneficial in tracking patient activity and thus evaluating the effect on clinical efficacy with integrated companion applications to capture patient-reported outcomes.
Thus, the change in the landscape of clinical trials is set to be positively impacted by the monitoring of data all through the product life cycle along with patient-reported data in real-time conditions, thus presenting an opportunistic growth for the dry powder inhaler market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat Are The Factors Restraining Demand For Dry Powder Inhalers?
Technological advancements are progressively growing in terms of increasing novel and innovative, integrated, alternative good manufacturing practice-ready approaches, which are associated with next-generation analytical and modelling skills. However, regulations encompassing such progressions are yet to catch up with the developing complex clinical requirements.
This trend is intensified by the acceleration of complexity and the cost of approval for the formulation of orally inhaled and nasal drug products and by the scientific disparity that still exists, particularly for locally acting dry powder inhaler products.
Considering this, despite existing development, animal models are not applicable to humans and perceptive methods for assessing clinical efficiency along with in-vitro and in-vivo association for inhaled medicines are still inadequate.
In this concern, the outcome of the clinical approach is intensely predisposed by the ambiguous correlation between efficiency and selected clinical endpoints. This risk is greater for therapies in which the pattern of deposition of the drug is directly associated with efficiency.
In spite of thorough assessments and a focus on advances in device design as well as formulation, the impact on the patient in terms of their adherence to therapy, inspiration rate, and correct use of the inhaler are yet to be quantified. This poses a restrictive impact on the growth of the dry powder inhaler market, given the wide-ranging factors associated with the intensity of the impact of disease on the patient, affecting their inspiration rate.
Country-Wise Insights
What Makes the U.S. the Largest Market for Dry Powder Inhalers?
The U.S. dominates the North American region with a total market share of about 90.5% in 2020, and is projected to continue experiencing high growth throughout the forecast period. U.S. is the most lucrative market for dry powder inhalers owing to the combination of a robust healthcare infrastructure accompanied with technologically advanced procedure, an increasing number of patients with respiratory disorders, strictly enforced guidelines by regulatory authorities pertaining to medical devices attributed with respiratory disorder therapeutics, and comparatively high government healthcare spending.
Furthermore, due to the increased prevalence of asthma and other respiratory disorders, as well as the growing geriatric population, the dry powder inhaler market in the United States is expected to develop significantly over the next decade.
Why is U.K. Considered a Lucrative Market for Dry Powder Inhalers in Europe?
U.K. is set to exhibit a CAGR of nearly 4.9% in the European dry powder inhaler market during the forecast period. The rising research and development activities to generate a sustainable base of drug delivery devices in the country as well as an established healthcare infrastructure are some of the factors aiding the growth of dry powder inhalers in the country.
What Makes China an Emerging Market for Dry Powder Inhalers?
China holds 38.9% share in the East Asia dry powder inhaler market in 2020, and is projected to increase at a CAGR rate of 5.4% during the forecast period. This growth is associated with the rising deployment of automated systems and devices into an integrated platform for patient monitoring as well as drug delivery devices, rising healthcare costs and rapidly improving medical infrastructure. All these factors are expected to drive market growth in the coming years in China.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-Wise Insights
Which Dry Powder Inhalers Product is Driving Market Growth?
Multi Dose dry powder inhalers project a lucrative growth at a CAGR of 4.6% till the end of the forecast period, with a market share of over 56.5% in 2020 owing to increasing demand and utilization worldwide. These inhalers dispense a multiple unit of dosage for a specified indication of the patient, ensuring quick deposition into the lungs, for improved patient outcome and are convenient and easy to use.
Which Indication is Largely of Focus in the Dry powder inhaler market?
Asthma holds a revenue share of 44.7% in 2020 in the global dry powder inhaler market and are projected to hold a share over the forecast period with the estimation being 42.8%. The global burden of respiratory diseases is quite large, and asthma is one of the most common respiratory diseases among the global population, owing to the rise in infectious diseases and the rising air pollution in the emerging economies.
Which Function Holds a Dominant Stance in the Global Dry powder inhaler market?
Manually operated inhaler devices holds a revenue share of 71.0% in 2020 and are projected to hold a share over the forecast period with the estimation being 71.4%. Since the dry powder inhalers are breath actuated, the device ensures the delivery of drugs in a much efficient manner, depending upon the patient’s aspiration rate and the force of inhalation.
Which End User Benefits The Most by Employment of Dry Powder Inhalers?
Institutional Sales lead the dry powder inhaler market with more than 48% market share in 2020. Most device prescriptions are made after careful assessment of the patient’s condition. Dry powder inhalers experience growing institutional sales owing to the physician based assessment and patient compliance.
What is the Impact of COVID-19 on the Dry Powder Inhalers Industry?
The epidemic has had a tremendous influence on various businesses around the world. This impact has shook the economy and pushed the system off balance.
Many people have died as a result of the spread of coronavirus over the world. This epidemic has resulted in a slew of breathing problems and lung disorders, which have been incredibly dangerous for persons who already have asthma, and is predicted to drive up demand for dry powder inhalers.
Breathlessness or shortness of breath is also a prevalent symptom among COVID-19 patients. This was expected to contribute to an increase in dry powder inhaler sales during epidemic.
Several key players extended their focus onto the development of novel and alternate drug delivery methods, with improved animal models to reduce cost and ensure successful clinical benefits.
However, during the recovery period, the dry powder inhaler market is expected to witness a boost in terms of sales, owing to the advancements in the device design and engineering, as well as its efficacy in the delivery of drugs through the pulmonary pathway.
Competitive Landscape
Leading players in the dry powder inhaler market are focusing their efforts on producing next generation products and adopting patient centric approaches in the development of innovative dry powder inhaler devices to maximise penetration of the product and its utilization across the globe.
Additionally, the market participants are investing money into new device architectures, powder formulations, and particle engineering research and development and are likely to continue to focus on improving particle qualities and developing efficient inhaler designs.
For instance:
- In September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced that the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.
- In August 2021, Pharmaxis granted Aptar Pharma, an exclusive option to develop and promote high payload dry powder inhalers.
Similarly, recent developments related to companies manufacturing dry powder inhalers products have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope As Per Dry Powder Inhalers Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa |
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, and South Africa |
|
Key Market Segments Covered |
Product, Indication, Function, End User and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered In Dry Powder Inhalers Industry Research
By Product :
- Single Dose Dry Powder Inhalers
- Multi Dose Dry Powder Inhalers
By Indication :
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Arterial Hypertension
- Diabetes
- Cystic Fibrosis
By Function :
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
By End User :
- Institutional Sales
- Hospital Pharmacies
- Cancer Research
- Office based Speciality Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
By Region :
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
The global dry powder inhaler market is worth US$ 18.9 Bn in 2021, and is set to expand 1.6X over the next ten years.
The dry powder inhaler market is expected to reach US$ 29.6 Bn by the end of 2031, with sales revenue expected to register 4.6% CAGR.
Utilization of physiologically-based pharmacokinetic models, development of advanced drug delivery systems, advanced inhaler device development and established guidelines on bioavailability/bioequivalence of inhaled products are some of the key trends being witnessed in this marketplace.
The U.S., Japan, China, U.K. and Germany are expected to drive demand for dry powder inhalers products.
North America is one of the key markets for dry powder inhalers, with the U.S. expected to account over 89.7% of the North American market during the forecast period.
Demand for dry powder inhalers in Europe is expected to register growth of 4.6% over the next ten years.
The U.S., China and Germany are key producers of dry powder inhalers products.
GlaxoSmithKline Plc, AstraZeneca Plc, Novartis AG, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Cipla Limited, Chiesi Farmaceutici S.p.A., Elpen S.A., Vectura Group Plc, Beximco Pharmaceuticals Ltd., Hovione, AptarGroup, Inc., Iconovo AB (Stevanato Group), Sava Healthcare Ltd., MannKind Corporation, Mylan N.V(a part of Viatris) and Pharmaxis are the key exporters of dry powder inhaler market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Road Map
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion
3. Key Market Trends
3.1. Key Trends Impacting The Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Key Regulations
4.2. Product USPs and Features
4.3. Strategic Promotional Activities
4.4. Dry Powder Inhaler Product Adoption, By Region
5. Global Dry Powder Inhaler Market Demand (in Volume Units) Analysis 2016-2020 and Forecast, 2021-2031
5.1. Historical Market Volume (Units) Analysis, 2016-2020
5.2. Current and Future Market Volume (Units) Projections, 2021-2031
5.2.1. Y-o-Y Growth Trend Analysis
6. Global Dry Powder Inhaler Market - Pricing Analysis
6.1. Global Average Pricing Analysis Benchmark
6.2. Regional Pricing Analysis, By Product
7. Global Dry Powder Inhaler Market Demand (in Value or Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Healthcare Expenditure Outlook
8.1.3. Growth of Healthcare Sector in Emerging nations
8.2. Forecast Factors - Relevance & Impact
8.2.1. Product Adoption Rate
8.2.2. Innovative Product Launches
8.2.3. Incidence of Chronic Respiratory Diseases
8.2.4. Digital Technology Integration
8.2.5. Cost of Device
8.2.6. Regulatory Scenario
8.3. Market Dynamics
8.3.1. Drivers
8.3.2. Restraints
8.3.3. Opportunity Analysis
9. COVID19 Crisis Analysis
9.1. Current COVID19 Statistics and Probable Future Impact
9.2. Current GDP Projection and Probable Impact
9.3. COVID19 and Impact Analysis
9.3.1. By Product
9.3.2. By Indication
9.3.3. By Function
9.3.4. By End User
9.3.5. By Country
10. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis by Product, 2016-2020
10.3. Current and Future Market Size (US$ Mn) and Forecast by Product, 2021-2031
10.3.1. Single Dose Dry Powder Inhalers
10.3.2. Multi Dose Dry Powder Inhalers
10.4. Market Attractiveness Analysis by Product
11. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Usage, 2016-2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Indication, 2021-2031
11.3.1. Asthma
11.3.2. Chronic Obstructive Pulmonary Disease (COPD)
11.3.3. Pulmonary Arterial Hypertension
11.3.4. Diabetes
11.3.5. Cystic Fibrosis
11.4. Market Attractiveness Analysis by Indication
12. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Function
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis by Function, 2016-2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Function, 2021-2031
12.3.1. Manually Operated Inhaler Devices
12.3.2. Digitally Operated Inhaler Devices
12.4. Market Attractiveness Analysis by Function
13. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis by End User, 2016-2020
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2021-2031
13.3.1. Institutional Sales
13.3.1.1. Hospital Pharmacies
13.3.1.2. Cancer Research
13.3.1.3. Office based Speciality Clinics
13.3.2. Retail Sales
13.3.2.1. Retail Pharmacies
13.3.2.2. Drug Stores
13.3.3. Mail Order Pharmacies
13.4. Market Attractiveness Analysis by End User
14. Global Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031, by Region
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis by Region, 2016-2020
14.3. Current Market Size (US$ Mn) Analysis and Forecast by Region, 2021-2031
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. Middle East and Africa (MEA)
14.3.5. South Asia
14.3.6. East Asia
14.3.7. Oceania
14.4. Market Attractiveness Analysis by Region
15. North America Dry Powder Inhaler Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
15.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. By Product
15.3.3. By Indication
15.3.4. By Function
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Indication
15.4.4. By Function
15.4.5. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Latin America Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
16.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Product
16.3.3. By Indication
16.3.4. By Function
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Indication
16.4.4. By Function
16.4.5. By End User
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Europe Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
17.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Rest of Europe
17.3.2. By Product
17.3.3. By Indication
17.3.4. By Function
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Indication
17.4.4. By Function
17.4.5. By End User
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. South Asia Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
18.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Thailand
18.3.1.3. Indonesia
18.3.1.4. Malaysia
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Indication
18.3.4. By Function
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Indication
18.4.4. By Function
18.4.5. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
19. East Asia Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
19.4. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
19.4.1. By Country
19.4.1.1. China
19.4.1.2. Japan
19.4.1.3. South Korea
19.4.2. By Product
19.4.3. By Indication
19.4.4. By Function
19.4.5. By End User
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Product
19.5.3. By Indication
19.5.4. By Function
19.5.5. By End User
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
20. Oceania Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
20.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Product
20.3.3. By Indication
20.3.4. By Function
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Indication
20.4.4. By Function
20.4.5. By End User
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis
21. Middle East and Africa Dry Powder Inhaler Market 2016-2020 and Forecast 2021-2031
21.1. Introduction
21.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2016-2020
21.3. Market Size (US$ Mn) Forecast by Market Taxonomy, 2021-2031
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. South Africa
21.3.1.3. Rest of Middle East and Africa
21.3.2. By Product
21.3.3. By Indication
21.3.4. By Function
21.3.5. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Indication
21.4.4. By Function
21.4.5. By End User
21.5. Key Market Participants - Intensity Mapping
21.6. Drivers and Restraints - Impact Analysis
22. Country Level Dry Powder Inhaler Market Analysis 2021 & 2031
22.1. Introduction
22.1.1. Market Value Proportion Analysis
22.1.2. Global VS. Country Growth Comparison
22.2. U.S. Dry Powder Inhaler Market Analysis
22.2.1. By Product
22.2.2. By Indication
22.2.3. By Function
22.2.4. By End User
22.3. Canada Dry Powder Inhaler Market Analysis
22.3.1. By Product
22.3.2. By Indication
22.3.3. By Function
22.3.4. By End User
22.4. Brazil Dry Powder Inhaler Market Analysis
22.4.1. By Product
22.4.2. By Indication
22.4.3. By Function
22.4.4. By End User
22.5. Mexico Dry Powder Inhaler Market Analysis
22.5.1. By Product
22.5.2. By Indication
22.5.3. By Function
22.5.4. By End User
22.6. Argentina Dry Powder Inhaler Market Analysis
22.6.1. By Product
22.6.2. By Indication
22.6.3. By Function
22.6.4. By End User
22.7. U.K. Dry Powder Inhaler Market Analysis
22.7.1. By Product
22.7.2. By Indication
22.7.3. By Function
22.7.4. By End User
22.8. Germany Dry Powder Inhaler Market Analysis
22.8.1. By Product
22.8.2. By Indication
22.8.3. By Function
22.8.4. By End User
22.9. France Dry Powder Inhaler Market Analysis
22.9.1. By Product
22.9.2. By Indication
22.9.3. By Function
22.9.4. By End User
22.10. Spain. Dry Powder Inhaler Market Analysis
22.10.1. By Product
22.10.2. By Indication
22.10.3. By Function
22.10.4. By End User
22.11. Italy Dry Powder Inhaler Market Analysis
22.11.1. By Product
22.11.2. By Indication
22.11.3. By Function
22.11.4. By End User
22.12. Russia Dry Powder Inhaler Market Analysis
22.12.1. By Product
22.12.2. By Indication
22.12.3. By Function
22.12.4. By End User
22.13. BENELUX Dry Powder Inhaler Market Analysis
22.13.1. By Product
22.13.2. By Indication
22.13.3. By Function
22.13.4. By End User
22.14. China Dry Powder Inhaler Market Analysis
22.14.1. By Product
22.14.2. By Indication
22.14.3. By Function
22.14.4. By End User
22.15. Japan Dry Powder Inhaler Market Analysis
22.15.1. By Product
22.15.2. By Indication
22.15.3. By Function
22.15.4. By End User
22.16. South Korea Dry Powder Inhaler Market Analysis
22.16.1. By Product
22.16.2. By Indication
22.16.3. By Function
22.16.4. By End User
22.17. India Dry Powder Inhaler Market Analysis
22.17.1. By Product
22.17.2. By Indication
22.17.3. By Function
22.17.4. By End User
22.18. Thailand Dry Powder Inhaler Market Analysis
22.18.1. By Product
22.18.2. By Indication
22.18.3. By Function
22.18.4. By End User
22.19. Indonesia Dry Powder Inhaler Market Analysis
22.19.1. By Product
22.19.2. By Indication
22.19.3. By Function
22.19.4. By End User
22.20. Malaysia Dry Powder Inhaler Market Analysis
22.20.1. By Product
22.20.2. By Indication
22.20.3. By Function
22.20.4. By End User
22.21. Australia Dry Powder Inhaler Market Analysis
22.21.1. By Product
22.21.2. By Indication
22.21.3. By Function
22.21.4. By End User
22.22. New Zealand Dry Powder Inhaler Market Analysis
22.22.1. By Product
22.22.2. By Indication
22.22.3. By Function
22.22.4. By End User
22.23. GCC Countries Dry Powder Inhaler Market Analysis
22.23.1. By Product
22.23.2. By Indication
22.23.3. By Function
22.23.4. By End User
22.24. South Africa Dry Powder Inhaler Market Analysis
22.24.1. By Product
22.24.2. By Indication
22.24.3. By Function
22.24.4. By End User
23. Market Structure Analysis
23.1. Market Analysis by Tier of Companies
23.2. Market Share Analysis of Top Players
23.3. Market Presence Analysis
23.3.1. By Regional Footprint of Players
23.3.2. Product Footprint by Players
23.3.3. Channel Footprint by Players
24. Competition Analysis
24.1. Competition Dashboard
24.2. Competition Benchmarking
24.3. Competition Deep Dive
24.3.1. GlaxoSmithKline Plc
24.3.1.1. Overview & Key Financials
24.3.1.2. Product Portfolio
24.3.1.3. Sales Footprint
24.3.1.4. Analyst commentary
24.3.1.5. Strategy
24.3.1.5.1. Marketing Strategy
24.3.1.5.2. Product Strategy
24.3.1.5.3. Channel Strategy
24.3.2. AstraZeneca Plc
24.3.2.1. Overview & Key Financials
24.3.2.2. Product Portfolio
24.3.2.3. Sales Footprint
24.3.2.4. Analyst commentary
24.3.2.5. Strategy
24.3.2.5.1. Marketing Strategy
24.3.2.5.2. Product Strategy
24.3.2.5.3. Channel Strategy
24.3.3. Novartis AG
24.3.3.1. Overview & Key Financials
24.3.3.2. Product Portfolio
24.3.3.3. Sales Footprint
24.3.3.4. Analyst commentary
24.3.3.5. Strategy
24.3.3.5.1. Marketing Strategy
24.3.3.5.2. Product Strategy
24.3.3.5.3. Channel Strategy
24.3.4. Teva Pharmaceutical Industries Limited
24.3.4.1. Overview & Key Financials
24.3.4.2. Product Portfolio
24.3.4.3. Sales Footprint
24.3.4.4. Analyst commentary
24.3.4.5. Strategy
24.3.4.5.1. Marketing Strategy
24.3.4.5.2. Product Strategy
24.3.4.5.3. Channel Strategy
24.3.5. Boehringer Ingelheim GmbH
24.3.5.1. Overview & Key Financials
24.3.5.2. Product Portfolio
24.3.5.3. Sales Footprint
24.3.5.4. Analyst commentary
24.3.5.5. Strategy
24.3.5.5.1. Marketing Strategy
24.3.5.5.2. Product Strategy
24.3.5.5.3. Channel Strategy
24.3.6. Cipla Limited
24.3.6.1. Overview & Key Financials
24.3.6.2. Product Portfolio
24.3.6.3. Sales Footprint
24.3.6.4. Analyst commentary
24.3.6.5. Strategy
24.3.6.5.1. Marketing Strategy
24.3.6.5.2. Product Strategy
24.3.6.5.3. Channel Strategy
24.3.7. Chiesi Farmaceutici S.p.A.
24.3.7.1. Overview & Key Financials
24.3.7.2. Product Portfolio
24.3.7.3. Sales Footprint
24.3.7.4. Analyst commentary
24.3.7.5. Strategy
24.3.7.5.1. Marketing Strategy
24.3.7.5.2. Product Strategy
24.3.7.5.3. Channel Strategy
24.3.8. Elpen S.A.
24.3.8.1. Overview & Key Financials
24.3.8.2. Product Portfolio
24.3.8.3. Sales Footprint
24.3.8.4. Analyst commentary
24.3.8.5. Strategy
24.3.8.5.1. Marketing Strategy
24.3.8.5.2. Product Strategy
24.3.8.5.3. Channel Strategy
24.3.9. Vectura Group Plc
24.3.9.1. Overview & Key Financials
24.3.9.2. Product Portfolio
24.3.9.3. Sales Footprint
24.3.9.4. Analyst commentary
24.3.9.5. Strategy
24.3.9.5.1. Marketing Strategy
24.3.9.5.2. Product Strategy
24.3.9.5.3. Channel Strategy
24.3.10. Beximco Pharmaceuticals Ltd.
24.3.10.1. Overview & Key Financials
24.3.10.2. Product Portfolio
24.3.10.3. Sales Footprint
24.3.10.4. Analyst commentary
24.3.10.5. Strategy
24.3.10.5.1. Marketing Strategy
24.3.10.5.2. Product Strategy
24.3.10.5.3. Channel Strategy
24.3.11. Hovione
24.3.11.1. Overview & Key Financials
24.3.11.2. Product Portfolio
24.3.11.3. Sales Footprint
24.3.11.4. Analyst commentary
24.3.11.5. Strategy
24.3.11.5.1. Marketing Strategy
24.3.11.5.2. Product Strategy
24.3.11.5.3. Channel Strategy
24.3.12. AptarGroup, Inc.
24.3.12.1. Overview & Key Financials
24.3.12.2. Product Portfolio
24.3.12.3. Sales Footprint
24.3.12.4. Analyst commentary
24.3.12.5. Strategy
24.3.12.5.1. Marketing Strategy
24.3.12.5.2. Product Strategy
24.3.12.5.3. Channel Strategy
24.3.13. Iconovo AB (Stevanato Group)
24.3.13.1. Overview & Key Financials
24.3.13.2. Product Portfolio
24.3.13.3. Sales Footprint
24.3.13.4. Analyst commentary
24.3.13.5. Strategy
24.3.13.5.1. Marketing Strategy
24.3.13.5.2. Product Strategy
24.3.13.5.3. Channel Strategy
24.3.14. Sava Healthcare Ltd.
24.3.14.1. Overview & Key Financials
24.3.14.2. Product Portfolio
24.3.14.3. Sales Footprint
24.3.14.4. Analyst commentary
24.3.14.5. Strategy
24.3.14.5.1. Marketing Strategy
24.3.14.5.2. Product Strategy
24.3.14.5.3. Channel Strategy
24.3.15. MannKind Corporation
24.3.15.1. Overview & Key Financials
24.3.15.2. Product Portfolio
24.3.15.3. Sales Footprint
24.3.15.4. Analyst commentary
24.3.15.5. Strategy
24.3.15.5.1. Marketing Strategy
24.3.15.5.2. Product Strategy
24.3.15.5.3. Channel Strategy
24.3.16. Mylan N.V(a part of Viatris)
24.3.16.1. Overview & Key Financials
24.3.16.2. Product Portfolio
24.3.16.3. Sales Footprint
24.3.16.4. Analyst commentary
24.3.16.5. Strategy
24.3.16.5.1. Marketing Strategy
24.3.16.5.2. Product Strategy
24.3.16.5.3. Channel Strategy
24.3.17. Pharmaxis
24.3.17.1. Overview & Key Financials
24.3.17.2. Product Portfolio
24.3.17.3. Sales Footprint
24.3.17.4. Analyst commentary
24.3.17.5. Strategy
24.3.17.5.1. Marketing Strategy
24.3.17.5.2. Product Strategy
24.3.17.5.3. Channel Strategy
25. Assumptions and Acronyms Used
26. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 02: Global Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 03: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 04: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 05: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 06: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Region
Table 07: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 08: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 09: North America Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 10: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 11: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 12: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 13: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 14: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 15: Latin America Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 16: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 17: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 18: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 19: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 20: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 21: Europe Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 22: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 23: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 24: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 25: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 26: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 27: South Asia Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 28: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 29: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 30: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 31: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 32: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 33: East Asia Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 34: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 35: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 36: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 37: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 38: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 39: Oceania Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 40: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 41: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 42: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Table 43: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Country
Table 44: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 45: MEA Dry Powder Inhaler Market Volume ('000) Analysis 2016–2020 and Forecast 2021–2031, by Product
Table 46: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Indication
Table 47: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by Function
Table 48: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis 2016–2020 and Forecast 2021–2031, by End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 02: Global Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 03: Global Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 04: Global Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 05: Global Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 06: Global Dry Powder Inhaler Market Volume ('000) Analysis, 2016-2020
Figure 07: Global Dry Powder Inhaler Market Volume ('000) & Y-o-Y Growth (%), 2021–2031
Figure 08: Global Average Pricing Analysis Benchmark USD (Unit) (2020)
Figure 09: Global Dry Powder Inhaler (Product: Single Dose Dry Powder Inhalers and Multi Dose Dry Powder Inhalers), Price Difference (US$) By Region, 2020
Figure 10: Global Dry Powder Inhaler (Product: Single Dose Dry Powder Inhalers and Multi Dose Dry Powder Inhalers), Price Difference (US$) By Region, 2031
Figure 11: Global Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 12: Global Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2021–2031
Figure 13: Global Dry Powder Inhaler Market Absolute $ Opportunity Analysis, 2021-2031
Figure 14: Global Dry Powder Inhaler Market Share Analysis (%) by Product, 2021 & 2031
Figure 15: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Product, 2020–2031
Figure 16: Global Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 17: Global Dry Powder Inhaler Market Share Analysis (%) by Indication, 2021 & 2031
Figure 18: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Indication, 2020–2031
Figure 19: Global Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 20: Global Dry Powder Inhaler Market Share Analysis (%) by Function, 2021 & 2031
Figure 21: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Function, 2020–2031
Figure 22: Global Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 23: Global Dry Powder Inhaler Market Share Analysis (%) by End User, 2021 & 2031
Figure 24: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by End User, 2020–2031
Figure 25: Global Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 26: Global Dry Powder Inhaler Market Share Analysis (%) by Region, 2021 & 2031
Figure 27: Global Dry Powder Inhaler Market Y-o-Y Growth (%) by Region, 2020–2031
Figure 28: Global Dry Powder Inhaler Market Attractiveness Analysis by Region, 2021–2031
Figure 29: North America Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 30: North America Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 31: North America Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 32: North America Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 33: North America Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 34: North America Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 35: North America Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 36: North America Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 37: North America Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 38: North America Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 39: North America Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 40: North America Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 41: Latin America Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 42: Latin America Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 43: Latin America Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 44: Latin America Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 45: Latin America Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 46: Latin America Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 47: Latin America Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 48: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 49: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 50: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 51: Latin America Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 52: Latin America Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 53: Europe Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 54: Europe Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 55: Europe Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 56: Europe Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 57: Europe Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 58: Europe Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 59: Europe Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 60: Europe Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 61: Europe Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 62: Europe Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 63: Europe Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 64: Europe Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 65: South Asia Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 66: South Asia Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 67: South Asia Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 68: South Asia Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 69: South Asia Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 70: South Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 71: South Asia Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 72: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 73: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 74: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 75: South Asia Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 76: South Asia Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 77: East Asia Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 78: East Asia Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 79: East Asia Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 80: East Asia Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 81: East Asia Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 82: East Asia Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 83: East Asia Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 84: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 85: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 86: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 87: East Asia Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 88: East Asia Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 89: Oceania Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 90: Oceania Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 91: Oceania Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 92: Oceania Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 93: Oceania Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 94: Oceania Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 95: Oceania Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 96: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 97: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 98: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 99: Oceania Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 100: Oceania Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 101: MEA Dry Powder Inhaler Market Share, By Product, 2021 (E)
Figure 102: MEA Dry Powder Inhaler Market Share, By Indication, 2021 (E)
Figure 103: MEA Dry Powder Inhaler Market Share, By Function, 2021 (E)
Figure 104: MEA Dry Powder Inhaler Market Share, By End User, 2021 (E)
Figure 105: MEA Dry Powder Inhaler Market Share, By Region, 2021 (E)
Figure 106: MEA Dry Powder Inhaler Market Value (US$ Mn) Analysis, 2016–2020
Figure 107: MEA Dry Powder Inhaler Market Value (US$ Mn) Forecast, 2020–2031
Figure 108: MEA Dry Powder Inhaler Market Attractiveness Analysis by Product, 2021–2031
Figure 109: MEA Dry Powder Inhaler Market Attractiveness Analysis by Indication, 2021–2031
Figure 110: MEA Dry Powder Inhaler Market Attractiveness Analysis by Function, 2021–2031
Figure 111: MEA Dry Powder Inhaler Market Attractiveness Analysis by End User, 2021–2031
Figure 112: MEA Dry Powder Inhaler Market Attractiveness Analysis by Country, 2021–2031
Figure 113: U.S. Market Value Proportion Analysis, 2021
Figure 114: Global Vs. U.S. Growth Comparison
Figure 115: U.S. Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 116: U.S. Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 117: U.S. Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 118: U.S. Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 119: Canada Market Value Proportion Analysis, 2021
Figure 120: Global Vs. Canada Growth Comparison
Figure 121: Canada Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 122: Canada Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 123: Canada Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 124: Canada Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 125: Brazil Market Value Proportion Analysis, 2021
Figure 126: Global Vs. Brazil Growth Comparison
Figure 127: Brazil Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 128: Brazil Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 129: Brazil Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 130: Brazil Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 131: Mexico Market Value Proportion Analysis, 2021
Figure 132: Global Vs. Mexico Growth Comparison
Figure 133: Mexico Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 134: Mexico Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 135: Mexico Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 136: Mexico Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 137: Argentina Market Value Proportion Analysis, 2021
Figure 138: Global Vs. Argentina Growth Comparison
Figure 139: Argentina Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 140: Argentina Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 141: Argentina Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 142: Argentina Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 143: U.K. Market Value Proportion Analysis, 2021
Figure 144: Global Vs. U.K. Growth Comparison
Figure 145: U.K. Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 146: U.K. Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 147: U.K. Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 148: U.K. Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 149: Germany Market Value Proportion Analysis, 2021
Figure 150: Global Vs. Germany Growth Comparison
Figure 151: Germany Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 152: Germany Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 153: Germany Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 154: Germany Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 155: France Market Value Proportion Analysis, 2021
Figure 156: Global Vs. France Growth Comparison
Figure 157: France Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 158: France Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 159: France Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 160: France Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 161: Spain Market Value Proportion Analysis, 2021
Figure 162: Global Vs. Spain Growth Comparison
Figure 163: Spain Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 164: Spain Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 165: Spain Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 166: Spain Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 167: Italy Market Value Proportion Analysis, 2021
Figure 168: Global Vs. Italy Growth Comparison
Figure 169: Italy Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 170: Italy Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 171: Italy Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 172: Italy Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 173: Russia Market Value Proportion Analysis, 2021
Figure 174: Global Vs. Russia Growth Comparison
Figure 175: Russia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 176: Russia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 177: Russia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 178: Russia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 179: BENELUX Market Value Proportion Analysis, 2021
Figure 180: Global Vs. BENELUX Growth Comparison
Figure 181: BENELUX Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 182: BENELUX Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 183: BENELUX Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 184: BENELUX Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 185: China Market Value Proportion Analysis, 2021
Figure 186: Global Vs. China Growth Comparison
Figure 187: China Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 188: China Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 189: China Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 190: China Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 191: Japan Market Value Proportion Analysis, 2021
Figure 192: Global Vs. Japan Growth Comparison
Figure 193: Japan Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 194: Japan Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 195: Japan Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 196: Japan Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 197: South Korea Market Value Proportion Analysis, 2021
Figure 198: Global Vs. South Korea Growth Comparison
Figure 199: South Korea Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 200: South Korea Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 201: South Korea Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 202: South Korea Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 203: India Market Value Proportion Analysis, 2021
Figure 204: Global Vs. India Growth Comparison
Figure 205: India Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 206: India Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 207: India Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 208: India Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 209: Thailand Market Value Proportion Analysis, 2021
Figure 210: Global Vs. Thailand Growth Comparison
Figure 211: Thailand Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 212: Thailand Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 213: Thailand Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 214: Thailand Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 215: Indonesia Market Value Proportion Analysis, 2021
Figure 216: Global Vs. Indonesia Growth Comparison
Figure 217: Indonesia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 218: Indonesia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 219: Indonesia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 220: Indonesia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 221: Malaysia Market Value Proportion Analysis, 2021
Figure 222: Global Vs. Malaysia Growth Comparison
Figure 223: Malaysia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 224: Malaysia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 225: Malaysia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 226: Malaysia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 227: Australia Market Value Proportion Analysis, 2021
Figure 228: Global Vs. Australia Growth Comparison
Figure 229: Australia Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 230: Australia Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 231: Australia Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 232: Australia Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 233: New Zealand Market Value Proportion Analysis, 2021
Figure 234: Global Vs. New Zealand Growth Comparison
Figure 235: New Zealand Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 236: New Zealand Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 237: New Zealand Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 238: New Zealand Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 239: GCC Countries Market Value Proportion Analysis, 2021
Figure 240: Global Vs. GCC Countries Growth Comparison
Figure 241: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 242: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 243: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 244: GCC Countries Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Figure 245: South Africa Market Value Proportion Analysis, 2021
Figure 246: Global Vs. South Africa Growth Comparison
Figure 247: South Africa Dry Powder Inhaler Market Share Analysis (%) By Product, 2021 & 2031
Figure 248: South Africa Dry Powder Inhaler Market Share Analysis (%) By Indication, 2021 & 2031
Figure 249: South Africa Dry Powder Inhaler Market Share Analysis (%) By Function, 2021 & 2031
Figure 250: South Africa Dry Powder Inhaler Market Share Analysis (%) By End User, 2021 & 2031
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
